242 related articles for article (PubMed ID: 36787106)
1. Spatial Transcriptomics Depict Ligand-Receptor Cross-talk Heterogeneity at the Tumor-Stroma Interface in Long-Term Ovarian Cancer Survivors.
Ferri-Borgogno S; Zhu Y; Sheng J; Burks JK; Gomez JA; Wong KK; Wong STC; Mok SC
Cancer Res; 2023 May; 83(9):1503-1516. PubMed ID: 36787106
[TBL] [Abstract][Full Text] [Related]
2. Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
Kelliher L; Lengyel E
Cancer Res; 2023 May; 83(9):1383-1385. PubMed ID: 37128849
[TBL] [Abstract][Full Text] [Related]
3. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
4. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Wang Z; Yang L; Su X; Wu X; Su R
J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
[TBL] [Abstract][Full Text] [Related]
6. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
7. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
[TBL] [Abstract][Full Text] [Related]
8. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer.
Yeung TL; Sheng J; Leung CS; Li F; Kim J; Ho SY; Matzuk MM; Lu KH; Wong STC; Mok SC
J Natl Cancer Inst; 2019 Mar; 111(3):272-282. PubMed ID: 29860390
[TBL] [Abstract][Full Text] [Related]
9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
10. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
[TBL] [Abstract][Full Text] [Related]
12. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
[TBL] [Abstract][Full Text] [Related]
14. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract][Full Text] [Related]
15. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Javellana M; Hoppenot C; Lengyel E
Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of immune related genes in high-grade ovarian serous carcinoma.
Siamakpour-Reihani S; Cobb LP; Jiang C; Zhang D; Previs RA; Owzar K; Nixon AB; Alvarez Secord A
Gynecol Oncol; 2020 Mar; 156(3):662-668. PubMed ID: 31918995
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]